Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Libtayo
Pharma
Regeneron lays out bright future for newest blockbuster Libtayo
Regeneron's PD-1 cancer treatment Libtayo, which continues to exceed analyst expectations, has become a blockbuster for the first time.
Kevin Dunleavy
Feb 4, 2025 11:28am
Regeneron touts Eylea HD launch, warns of potential approval delay
Aug 1, 2024 11:15am
Docs ask pharma for more NSCLC drugs, resources and research
Jan 25, 2024 6:30am
Regeneron passes some European Libtayo rights to Medison Pharma
Jan 8, 2024 3:47pm
Regeneron's Libtayo delivers lung cancer win with BMS' Yervoy
Dec 1, 2022 12:25pm
Regeneron's Libtayo finally scores Keytruda-matching NSCLC nod
Nov 9, 2022 9:15am
